Item 8.01 Other Events.



On May 16, 2022, Travere Therapeutics, Inc. (the "Company") announced that the
U.S. Food and Drug Administration ("FDA") has accepted and granted Priority
Review of its New Drug Application ("NDA") under Subpart H for accelerated
approval of sparsentan for the treatment of IgA nephropathy ("IgAN"). The FDA
has indicated that it is not currently planning to hold an advisory committee
meeting to discuss the application and has assigned a Prescription Drug User Fee
Act (PDUFA) target action date of November 17, 2022.

Forward-Looking Statements



This Current Report on Form 8-K contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include references relating to the FDA's potential
approval of the Company's NDA for sparsentan for the treatment of IgAN by the
target action date of November 17, 2022, or at all, and the expectation around
any potential future request by the FDA to hold an advisory committee meeting
related to the application. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including factors
that could delay, divert or change any of them, and could cause actual outcomes
and results to differ materially from current expectations. No forward-looking
statement can be guaranteed. Among the factors that could cause actual results
to differ materially from those indicated in the forward-looking statements are
risks and uncertainties associated with the regulatory review and approval
process, including the Subpart H accelerated approval pathway. There is no
guarantee that the FDA will grant accelerated approval of sparsentan for IgAN or
that sparsentan will be approved at all. In addition, such risks and
uncertainties may include those described in the Company's filings with the
Securities and Exchange Commission, including under the "Risk Factors" heading
of the Company's quarterly report on Form 10-Q for the quarter ended March 31,
2022, as filed with the SEC on May 5, 2022. You are cautioned not to place undue
reliance on any forward-looking statements as there are important factors that
could cause actual results to differ materially from those in any
forward-looking statements, many of which are beyond our control. Except to the
extent required by law, the Company undertakes no obligation to publicly update
any forward-looking statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description


      104              Cover Page Interactive Data File (embedded within the Inline XBRL document).







--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.

Dated: May 16, 2022                                                    By:

/s/ Elizabeth E. Reed

Name: Elizabeth E. Reed

Senior Vice President, General

Title: Counsel and Secretary

© Edgar Online, source Glimpses